Hyloris Developmentsen Sa (HYL) - Total Liabilities

Latest as of June 2025: €8.16 Million EUR ≈ $9.54 Million USD

Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has total liabilities worth €8.16 Million EUR (≈ $9.54 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hyloris Developmentsen Sa cash conversion from operations to assess how effectively this company generates cash.

Hyloris Developmentsen Sa - Total Liabilities Trend (2016–2024)

This chart illustrates how Hyloris Developmentsen Sa's total liabilities have evolved over time, based on quarterly financial data. Check HYL asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Hyloris Developmentsen Sa Competitors by Total Liabilities

The table below lists competitors of Hyloris Developmentsen Sa ranked by their total liabilities.

Company Country Total Liabilities
Samhwa Paint
KO:000390
Korea ₩280.08 Billion
Lindsay Australia Ltd
AU:LAU
Australia AU$553.18 Million
Quanterix Corp
NASDAQ:QTRX
USA $129.61 Million
Woongjin Co Ltd
KO:016880
Korea ₩4.82 Trillion
Quipt Home Medical Corp
NASDAQ:QIPT
USA $167.66 Million
KEYEAST.Co.Ltd
KQ:054780
Korea ₩19.16 Billion
Eastern Water Resources Development and Management Public Company Limited
BK:EASTW
Thailand ฿16.37 Billion
Donga Geologic
KO:028100
Korea ₩214.80 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Hyloris Developmentsen Sa's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HYL market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hyloris Developmentsen Sa's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hyloris Developmentsen Sa (2016–2024)

The table below shows the annual total liabilities of Hyloris Developmentsen Sa from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €9.19 Million
≈ $10.75 Million
+6.73%
2023-12-31 €8.61 Million
≈ $10.07 Million
+26.29%
2022-12-31 €6.82 Million
≈ $7.97 Million
-55.69%
2021-12-31 €15.39 Million
≈ $17.99 Million
+52.01%
2020-12-31 €10.12 Million
≈ $11.83 Million
-37.40%
2019-12-31 €16.17 Million
≈ $18.91 Million
+30.31%
2018-12-31 €12.41 Million
≈ $14.51 Million
+43.45%
2017-12-31 €8.65 Million
≈ $10.11 Million
+144.86%
2016-12-31 €3.53 Million
≈ $4.13 Million
--

About Hyloris Developmentsen Sa

BR:HYL Belgium Biotechnology
Market Cap
$158.77 Million
€135.80 Million EUR
Market Cap Rank
#17407 Global
#73 in Belgium
Share Price
€4.85
Change (1 day)
-8.14%
52-Week Range
€4.60 - €8.10
All Time High
€18.90
About

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more